Barely Significant
← all phrases

nominally significant

7,733 sentences · 7,733 papers · 9,414 search hits before verification · confirmed specimen

Sighted at

p=0.08

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

nominally significantp < 0.051.0× alphagold
Additional post hoc analyses show that these SNVs remain suggestively significant ( p < 5 × 10 −5 ) when not covarying for APOE and the HRs remain in the same direction and nominally significant ( p < 0.05) when using models that include APOE ε2 and ε4 separately in dominant and additive models (Table S4 in supporting information). 3.2.2 APOE analyses Next, in Cox proportional hazard (PH) models, carriers of ε2/ε4, ε3/ε4, ε4/ε4 had an elevated HR (Cox PH HR > 1) for earlier conversion to amyloid positivity compared to ε3/ε3 homozygotes. ε2/ε3 carriers demonstrated a lower risk ratio (Cox PH HR < 1; Table 3 ).
nominally significantp < 0.051.0× alphagold
When assessing each FTD syndrome separately, significant ( p < 0.0062) or nominally significant ( p < 0.05) associations with GFAP were seen for nfvPPA (phonemic fluency), svPPA (Digit span backward and Trails B), CBS (CDR® + NACC-FTLDsb, MoCA and Digit Span Backward), PSP-RS (CDR® + NACC-FTLDsb, MoCA and MINT), and MBCI (category fluency).
nominally significantp < 0.051.0× alphagold
3.4 Multivariate regression to maximize the association with subjective cognitive decline scores All variables which were nominally significant (p < 0.05) in the competitive model analysis, in addition to covariates, were then selected as input variables in a backwards stepwise multiple regression analysis to maximize the R adj 2 value ( Fig. 3 A ).
nominally significantp < 0.051.0× alphagold
Despite limited overlap at the single-metabolite level between the two overall OC outcomes, we observed greater concordance at the pathway level: among nominally significant pathways (raw p < 0.05), arginine and proline metabolism and beta-alanine metabolism overlapped across the two outcomes ( Figure 1 E; Supplementary Table S4 ).
nominally significantP < 0.051.0× alphagold
In patients with moderate or severe DED ( n = 53), PL9643 treatment demonstrated either nominally significant ( P < 0.05) or trending ( P < 0.1) improvement over placebo in mean change from baseline at week 12/day 85 in several sign endpoints, including fluorescein staining in inferior, superior, corneal sum, and total sum regions; Lissamine Green staining in temporal, nasal, conjunctival sum, and total sum regions; and tear film breakup time.